Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 3 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 3.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Mark McKenna is the Chief Investment Officer and Managing Director of McKenna Capital Partners and serves as a board member for Prometheus Biosciences and Chairman of the Board for Apogee Therapeutics.
Mark McKenna is a director whose term expires at the company's first annual general meeting. He is associated with a family office dedicated to investing in breakthrough treatments for debilitating diseases, and previously served at Prometheus. Prior to that, he was a corporate officer of Bausch Health and President of its subsidiary Salix Pharmaceuticals from 2016 to 2019, after serving at Bausch + Lomb from 2006 to 2016 and beginning his career at Johnson & Johnson from 2002 to 2006. He holds a degree in Marketing from Arizona State University, an MBA from Azusa Pacific University, and completed the Wharton Fellows program at the Wharton School of Business.
[Origin not recorded. Carried over from /people/mckenna-mark-c-9623, a second record for the same person.]
This record is keyed to SEC CIK 0001749623 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 10 institutional-holder rows on these vehicles, under 8 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.